Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (47 quarters reported)
$105M in Q4 2014 → $163M now. Hover for any quarter.
As reported for the quarter ended June 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Monte Rosa Therapeutics, Inc. | 47.3% | Unchanged | 3,180,780 | $77M |
| Century Therapeutics, Inc. | 18.3% | Unchanged | 12,166,109 | $29.8M |
| Jade Biosciences, Inc. | 13.6% | Trimmed 35% | 991,783 | $22M |
| Lenz Therapeutics, Inc. | 9.3% | Unchanged | 2,656,888 | $15.1M |
| Contineum Therapeutics, Inc. | 5.5% | Unchanged | 542,628 | $8.89M |
| Crispr Therapeutics Ag | 5.0% | Unchanged | 148,831 | $8.12M |
| Skye Bioscience, Inc. | 0.9% | Unchanged | 2,007,704 | $1.39M |
| Tempest Therapeutics, Inc. | 0.2% | Unchanged | 269,772 | $299K |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended June 30, 2026 · filed August 12, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Jade Biosciences, Inc. | Trimmed | −534,037 | −$11.9M | 13.6% |
quarter ended March 31, 2026 · filed May 05, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Century Therapeutics, Inc. | New | +12,166,109 | +$27.5M | 19.4% |
| Monte Rosa Therapeutics, Inc. | Trimmed | −1,201,907 | −$19.8M | 37.0% |
quarter ended December 31, 2025 · filed February 12, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Monte Rosa Therapeutics, Inc. | Trimmed | −1,270,235 | −$19.9M | 45.5% |
| Repare Therapeutics, Inc. | Exited | −2,646,657 | −$4.66M | — |
| Adverum Biotechnologies, Inc. | Exited | −506,821 | −$2.3M | — |
quarter ended September 30, 2025 · filed November 10, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Lenz Therapeutics, Inc. | New | +2,656,888 | +$124M | 58.3% |
| Crispr Therapeutics Ag | Trimmed | −349,727 | −$22.7M | 4.5% |
quarter ended June 30, 2025 · filed August 11, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Jade Biosciences, Inc. | New | +1,525,820 | +$15.2M | 18.6% |
| Tempest Therapeutics, Inc. | Exited | −3,507,055 | −$2.59M | — |
| Tempest Therapeutics, Inc. | New | +269,772 | +$1.83M | 2.2% |
| Contineum Therapeutics, Inc. | Trimmed | −375,535 | −$1.49M | 2.6% |
quarter ended March 31, 2025 · filed May 07, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Tempest Therapeutics, Inc. | Exited | −3,507,055 | −$2.93M | — |
| Tempest Therapeutics, Inc. | New | +3,507,055 | +$2.59M | 4.3% |
quarter ended December 31, 2024 · filed February 12, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Monte Rosa Therapeutics, Inc. | New | +5,652,922 | +$39.2M | 45.2% |
| Tempest Therapeutics, Inc. | New | +3,507,055 | +$2.93M | 3.4% |
| GO Gritstone Oncology, Inc. | Exited | −3,561,150 | −$2.07M | — |
quarter ended September 30, 2024 · filed November 08, 2024
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Passage Bio, Inc. | Exited | −4,026,417 | −$3.2M | — |
| Aligos Therapeutics, Inc. | Exited | −1,457,937 | −$510K | — |
Loading...
